BLAINJECTIONINJECTABLE
Approved
Sep 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BOSAYA (denosumab-kyqq) by Biocon is rank ligand blocking activity [moa]. Approved for osteoporosis, bone metastases, breast cancer and 1 more indications. First approved in 2025.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BOSAYA is a monoclonal antibody biosimilar to denosumab that blocks RANK ligand to inhibit osteoclast formation and bone resorption. It treats osteoporosis and bone metastases across multiple cancer types including breast and prostate cancer. The drug is administered via subcutaneous injection and represents a cost-competitive entry into the denosumab market.
Launch
Early-stage biosimilar launch with moderate competitive pressure (30/100); team will focus on payer negotiations, market access, and rapid penetration of the osteoporosis and oncology segments.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications (4)
Worked on BOSAYA at Biocon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.